• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

由H1047R突变型PI3K引发的结肠癌肿瘤发生

Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.

作者信息

Yueh Alexander E, Payne Susan N, Leystra Alyssa A, Van De Hey Dana R, Foley Tyler M, Pasch Cheri A, Clipson Linda, Matkowskyj Kristina A, Deming Dustin A

机构信息

Division of Hematology and Oncology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, United States of America.

University of Wisconsin Carbone Cancer Center, Madison, WI, United States of America.

出版信息

PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016.

DOI:10.1371/journal.pone.0148730
PMID:26863299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4749659/
Abstract

The phosphoinositide 3-kinase (PI3K) signaling pathway is critical for multiple important cellular functions, and is one of the most commonly altered pathways in human cancers. We previously developed a mouse model in which colon cancers were initiated by a dominant active PI3K p110-p85 fusion protein. In that model, well-differentiated mucinous adenocarcinomas developed within the colon and initiated through a non-canonical mechanism that is not dependent on WNT signaling. To assess the potential relevance of PI3K mutations in human cancers, we sought to determine if one of the common mutations in the human disease could also initiate similar colon cancers. Mice were generated expressing the Pik3caH1047R mutation, the analog of one of three human hotspot mutations in this gene. Mice expressing a constitutively active PI3K, as a result of this mutation, develop invasive adenocarcinomas strikingly similar to invasive adenocarcinomas found in human colon cancers. These tumors form without a polypoid intermediary and also lack nuclear CTNNB1 (β-catenin), indicating a non-canonical mechanism of tumor initiation mediated by the PI3K pathway. These cancers are sensitive to dual PI3K/mTOR inhibition indicating dependence on the PI3K pathway. The tumor tissue remaining after treatment demonstrated reduction in cellular proliferation and inhibition of PI3K signaling.

摘要

磷酸肌醇3激酶(PI3K)信号通路对多种重要的细胞功能至关重要,是人类癌症中最常发生改变的信号通路之一。我们之前构建了一种小鼠模型,其中结肠癌由显性激活的PI3K p110-p85融合蛋白引发。在该模型中,结肠内形成了高分化黏液腺癌,其通过一种不依赖WNT信号的非经典机制引发。为了评估PI3K突变在人类癌症中的潜在相关性,我们试图确定人类疾病中常见的突变之一是否也能引发类似的结肠癌。构建了表达Pik3caH1047R突变的小鼠,该突变是该基因三个人类热点突变之一的类似物。由于这种突变而表达组成型激活PI3K的小鼠会发生侵袭性腺癌,与人类结肠癌中发现的侵袭性腺癌惊人地相似。这些肿瘤在没有息肉样中间阶段的情况下形成,并且也缺乏核CTNNB1(β-连环蛋白),表明由PI3K途径介导的肿瘤起始的非经典机制。这些癌症对PI3K/mTOR双重抑制敏感,表明对PI3K途径有依赖性。治疗后剩余的肿瘤组织显示细胞增殖减少且PI3K信号受到抑制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/60ea7db32eb5/pone.0148730.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/d98fedaaea9b/pone.0148730.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/0727b94294aa/pone.0148730.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/11e66f169595/pone.0148730.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/e15afcd19a8e/pone.0148730.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/9dc658fe3bd5/pone.0148730.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/60ea7db32eb5/pone.0148730.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/d98fedaaea9b/pone.0148730.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/0727b94294aa/pone.0148730.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/11e66f169595/pone.0148730.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/e15afcd19a8e/pone.0148730.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/9dc658fe3bd5/pone.0148730.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/69cd/4749659/60ea7db32eb5/pone.0148730.g006.jpg

相似文献

1
Colon Cancer Tumorigenesis Initiated by the H1047R Mutant PI3K.由H1047R突变型PI3K引发的结肠癌肿瘤发生
PLoS One. 2016 Feb 10;11(2):e0148730. doi: 10.1371/journal.pone.0148730. eCollection 2016.
2
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.mTOR 抑制在依赖 PI3K 的结肠癌细胞中引发显著反应。
PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013.
3
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.PIK3CA和APC突变在肠道癌的发展中具有协同作用。
Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27.
4
Mice expressing activated PI3K rapidly develop advanced colon cancer.表达激活的 PI3K 的小鼠迅速发展为晚期结肠癌。
Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23.
5
Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.信号转导和转录激活因子3(STAT3)、β-连环蛋白和胰岛素样生长因子1受体(IGF-1R)的抑制剂可使小鼠PIK3CA突变型乳腺癌对PI3K抑制剂敏感。
Mol Oncol. 2017 May;11(5):552-566. doi: 10.1002/1878-0261.12053. Epub 2017 Apr 6.
6
Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.WNT/β-catenin 信号的激活导致携带 PIK3CA 突变的结直肠癌细胞对双 PI3K/mTOR 抑制剂产生耐药性。
Int J Cancer. 2019 Jan 15;144(2):389-401. doi: 10.1002/ijc.31662. Epub 2018 Nov 29.
7
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.KRAS 和 PIK3CA 共存突变影响双重 PI3K/MTOR 抑制剂 NVP-BEZ235 调节结直肠癌中 PI3K/MTOR 通路的疗效。
Int J Cancer. 2013 Aug 15;133(4):984-96. doi: 10.1002/ijc.28073. Epub 2013 Mar 8.
8
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.NVP-BEZ235,一种双PI3K/mTOR抑制剂,可阻止PI3K信号传导并抑制具有激活PI3K突变的癌细胞的生长。
Cancer Res. 2008 Oct 1;68(19):8022-30. doi: 10.1158/0008-5472.CAN-08-1385.
9
The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.双重 PI3K/mTOR 抑制剂 BEZ235 可限制肺癌肿瘤的生长,而与 EGFR 状态无关,是联合治疗方案中的有力辅助药物。
J Exp Clin Cancer Res. 2019 Jul 1;38(1):282. doi: 10.1186/s13046-019-1282-0.
10
Assessment of the In Vivo Activity of PI3K and MEK Inhibitors in Genetically Defined Models of Colorectal Cancer.在基因定义的结直肠癌模型中评估PI3K和MEK抑制剂的体内活性
Mol Cancer Ther. 2015 Oct;14(10):2175-86. doi: 10.1158/1535-7163.MCT-15-0223. Epub 2015 Jul 23.

引用本文的文献

1
Prevalence and effect of H1047R somatic mutation among Indian head and neck cancer patients.印度头颈癌患者中H1047R体细胞突变的患病率及影响
Saudi J Biol Sci. 2024 Aug;31(8):104029. doi: 10.1016/j.sjbs.2024.104029. Epub 2024 May 27.
2
Experimental Murine Models for Colorectal Cancer Research.用于结直肠癌研究的实验性小鼠模型
Cancers (Basel). 2023 Apr 30;15(9):2570. doi: 10.3390/cancers15092570.
3
Multi-ancestral origin of intestinal tumors: Impact on growth, progression, and drug efficacy.肠道肿瘤的多祖起源:对生长、进展和药物疗效的影响。

本文引用的文献

1
PIK3CA mutations can initiate pancreatic tumorigenesis and are targetable with PI3K inhibitors.磷脂酰肌醇-3激酶催化亚基α(PIK3CA)突变可引发胰腺肿瘤发生,且可被PI3K抑制剂靶向作用。
Oncogenesis. 2015 Oct 5;4(10):e169. doi: 10.1038/oncsis.2015.28.
2
Drugging PI3K in cancer: refining targets and therapeutic strategies.癌症中PI3K的药物治疗:优化靶点与治疗策略
Curr Opin Pharmacol. 2015 Aug;23:98-107. doi: 10.1016/j.coph.2015.05.016. Epub 2015 Jun 25.
3
Serrated neoplasia-role in colorectal carcinogenesis and clinical implications.锯齿状肿瘤-在结直肠肿瘤发生中的作用及其临床意义。
Cancer Rep (Hoboken). 2022 Feb;5(2):e1459. doi: 10.1002/cnr2.1459. Epub 2021 Jul 10.
4
Role of radical quenching activity of dihydrocanaric acid in the treatment of cancer-experimental and theoretical.二氢卡纳酸的自由基猝灭活性在癌症治疗中的作用——实验与理论研究
3 Biotech. 2020 Jun;10(6):251. doi: 10.1007/s13205-020-02221-5. Epub 2020 May 13.
5
Characterization of an Amphiphilic Phosphonated Calixarene Carrier Loaded With Carboplatin and Paclitaxel: A Preliminary Study to Treat Colon Cancer and .负载卡铂和紫杉醇的两亲性膦酸化杯芳烃载体的表征:治疗结肠癌的初步研究及…… (原文结尾不完整)
Front Bioeng Biotechnol. 2019 Oct 1;7:238. doi: 10.3389/fbioe.2019.00238. eCollection 2019.
6
Oncogenic promotes cellular stemness in an allele dose-dependent manner.致癌基因以等位基因剂量依赖的方式促进细胞干性。
Proc Natl Acad Sci U S A. 2019 Apr 23;116(17):8380-8389. doi: 10.1073/pnas.1821093116. Epub 2019 Apr 4.
7
Molecular Profiles Guide Colorectal Cancer Treatment.分子图谱指导结直肠癌治疗。
Fed Pract. 2016 May;33(Suppl 4):50S-53S.
8
Activating Mutations in Contribute to Anal Carcinogenesis in the Presence or Absence of HPV-16 Oncogenes.激活突变有助于 HPV-16 致癌基因存在或缺失时的肛门癌发生。
Clin Cancer Res. 2019 Mar 15;25(6):1889-1900. doi: 10.1158/1078-0432.CCR-18-2843. Epub 2018 Dec 7.
9
MTORC1/2 Inhibition as a Therapeutic Strategy for Mutant Cancers.MTORC1/2 抑制作为治疗突变癌症的一种策略。
Mol Cancer Ther. 2019 Feb;18(2):346-355. doi: 10.1158/1535-7163.MCT-18-0510. Epub 2018 Nov 13.
10
Cancer-Associated PIK3CA Mutations in Overgrowth Disorders.肿瘤相关 PIK3CA 突变与过度生长疾病。
Trends Mol Med. 2018 Oct;24(10):856-870. doi: 10.1016/j.molmed.2018.08.003. Epub 2018 Sep 6.
Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):401-9. doi: 10.1038/nrgastro.2015.73. Epub 2015 May 12.
4
Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.帕唑帕尼与依维莫司联合用于PIK3CA突变阳性/PTEN缺失且对标准治疗难治的晚期实体瘤患者的I期研究
Invest New Drugs. 2015 Jun;33(3):700-9. doi: 10.1007/s10637-015-0238-2. Epub 2015 Apr 24.
5
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.依鲁替尼治疗复发惰性淋巴瘤患者的 PI3Kδ 抑制作用。
N Engl J Med. 2014 Mar 13;370(11):1008-18. doi: 10.1056/NEJMoa1314583. Epub 2014 Jan 22.
6
PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.PI3K 通过 Rac-GEF,P-Rex1 调节乳腺癌中的 MEK/ERK 信号。
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21124-9. doi: 10.1073/pnas.1314124110. Epub 2013 Dec 10.
7
PIK3CA and APC mutations are synergistic in the development of intestinal cancers.PIK3CA和APC突变在肠道癌的发展中具有协同作用。
Oncogene. 2014 Apr 24;33(17):2245-54. doi: 10.1038/onc.2013.167. Epub 2013 May 27.
8
mTOR inhibition elicits a dramatic response in PI3K-dependent colon cancers.mTOR 抑制在依赖 PI3K 的结肠癌细胞中引发显著反应。
PLoS One. 2013 Apr 9;8(4):e60709. doi: 10.1371/journal.pone.0060709. Print 2013.
9
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials.PIK3CA 突变 H1047R 与早期临床试验中对 PI3K/AKT/mTOR 信号通路抑制剂的反应相关。
Cancer Res. 2013 Jan 1;73(1):276-84. doi: 10.1158/0008-5472.CAN-12-1726. Epub 2012 Oct 12.
10
Mice expressing activated PI3K rapidly develop advanced colon cancer.表达激活的 PI3K 的小鼠迅速发展为晚期结肠癌。
Cancer Res. 2012 Jun 15;72(12):2931-6. doi: 10.1158/0008-5472.CAN-11-4097. Epub 2012 Apr 23.